

Anthem Health Plans Kentucky, Inc. dba Anthem Blue Cross and Blue Shield in

Anthem Health Plans Kentucky, Inc. dba Anthem Blue Cross and Blue Shield in Kentucky (Org ID: 729, SubID: 11884, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014

The Auditor lock has been applied to this submission.

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	NA	R	Denominator fewer than 30
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				NA	R	Denominator fewer than 30
<i>Counseling for Nutrition</i>				NA	R	Denominator fewer than 30
<i>Counseling for Physical Activity</i>				NA	R	Denominator fewer than 30
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				NA	R	Denominator fewer than 30
<i>IPV</i>				NA	R	Denominator fewer than 30
<i>MMR</i>				NA	R	Denominator fewer than 30
<i>HiB</i>				NA	R	Denominator fewer than 30
<i>Hepatitis B</i>				NA	R	Denominator fewer than 30
<i>VZV</i>				NA	R	Denominator fewer than 30
<i>Pneumococcal Conjugate</i>				NA	R	Denominator fewer than 30
<i>Hepatitis A</i>				NA	R	Denominator fewer than 30
<i>Rotavirus</i>				NA	R	Denominator fewer than 30
<i>Influenza</i>				NA	R	Denominator fewer than 30
<i>Combination #2</i>				NA	R	Denominator fewer than 30
<i>Combination #3</i>				NA	R	Denominator fewer than 30
<i>Combination #4</i>				NA	R	Denominator fewer than 30
<i>Combination #5</i>				NA	R	Denominator fewer than 30
<i>Combination #6</i>				NA	R	Denominator fewer than 30
<i>Combination #7</i>				NA	R	Denominator fewer than 30

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
<i>Combination #8</i>				NA	R	Denominator fewer than 30
<i>Combination #9</i>				NA	R	Denominator fewer than 30
<i>Combination #10</i>				NA	R	Denominator fewer than 30
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				NA	R	Denominator fewer than 30
<i>Tdap/Td</i>				NA	R	Denominator fewer than 30
<i>Combination #1</i>				NA	R	Denominator fewer than 30
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			NA	R	Denominator fewer than 30
Lead Screening in Children (lsc)	Y		N	NA	R	Denominator fewer than 30
Breast Cancer Screening (bcs)	Y			NA	R	Denominator fewer than 30
Cervical Cancer Screening (ccs)	Y			25.29%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			13.13%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				44.62%	R	Reportable
<i>21-24 Years</i>				53.00%	R	Reportable
<i>Total</i>				51.27%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		NA	R	Denominator fewer than 30
Appropriate Treatment for Children With URI (uri)	Y	Y		NA	R	Denominator fewer than 30
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		27.56%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			NA	R	Denominator fewer than 30
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				63.73%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
<i>Bronchodilator</i>				71.48%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				NA	R	Denominator fewer than 30
<i>12-18 Years</i>				NA	R	Denominator fewer than 30
<i>19-50 Years</i>				NA	R	Denominator fewer than 30
<i>51-64 Years</i>				NA	R	Denominator fewer than 30
<i>Total</i>				NA	R	Denominator fewer than 30
Medication Management for People With Asthma (mma)	Y	Y				
<i>5-11 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>5-11 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>12-18 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>12-18 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>19-50 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>19-50 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>51-64 Years - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>51-64 Years - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
<i>Total - Medication Compliance 50%</i>				NA	R	Denominator fewer than 30
<i>Total - Medication Compliance 75%</i>				NA	R	Denominator fewer than 30
Asthma Medication Ratio (amr)	Y	Y				
<i>5-11 Years</i>				NA	R	Denominator fewer than 30
<i>12-18 Years</i>				NA	R	Denominator fewer than 30
<i>19-50 Years</i>				NA	R	Denominator fewer than 30
<i>51-64 Years</i>				NA	R	Denominator fewer than 30
<i>Total</i>				NA	R	Denominator fewer than 30
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			52.79%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		71.43%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				90.89%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>				51.14%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				38.70%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				26.20%	R	Reportable
<i>Eye Exam (Retinal) Performed</i>				34.68%	R	Reportable
<i>Medical Attention for Nephropathy</i>				84.06%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				58.14%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		63.64%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			55.18%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				69.55%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				62.05%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				NA	R	Denominator fewer than 30
<i>Continuation and Maintenance (C&M) Phase</i>				NA	R	Denominator fewer than 30
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				37.02%	R	Reportable
<i>7-Day Follow-Up</i>				20.52%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		82.93%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			NA	R	Denominator fewer than 30
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		57.14%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
1-5 Years				NA	R	Denominator fewer than 30
6-11 Years				NA	R	Denominator fewer than 30
12-17 Years				NA	R	Denominator fewer than 30
Total				NA	R	Denominator fewer than 30
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
1-5 Years				NA	R	Denominator fewer than 30
6-11 Years				NA	R	Denominator fewer than 30
12-17 Years				NA	R	Denominator fewer than 30
Total				NA	R	Denominator fewer than 30
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
ACE Inhibitors or ARBs				90.15%	R	Reportable
Digoxin				NA	R	Denominator fewer than 30
Diuretics				90.62%	R	Reportable
Total				90.10%	R	Reportable
Access/Availability of Care						

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
20-44 Years				74.61%	R	Reportable
45-64 Years				84.17%	R	Reportable
65+ Years				NA	R	Denominator fewer than 30
Total				78.49%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
12-24 Months				NA	R	Denominator fewer than 30
25 Months - 6 Years				NA	R	Denominator fewer than 30
7-11 Years				NA	R	Denominator fewer than 30
12-19 Years				NA	R	Denominator fewer than 30
Annual Dental Visit (adv)	Y	Y				
2-3 Years				NA	R	Denominator fewer than 30
4-6 Years				NA	R	Denominator fewer than 30
7-10 Years				NA	R	Denominator fewer than 30
11-14 Years				NA	R	Denominator fewer than 30
15-18 Years				NA	R	Denominator fewer than 30
19-21 Years				21.68%	R	Reportable
Total				21.49%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				NA	R	Denominator fewer than 30
Engagement of AOD Treatment: 13-17 Years				NA	R	Denominator fewer than 30
Initiation of AOD Treatment: 18+ Years				34.29%	R	Reportable
Engagement of AOD Treatment: 18+ Years				9.89%	R	Reportable
Initiation of AOD Treatment: Total				34.32%	R	Reportable
Engagement of AOD Treatment: Total				9.87%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				64.29%	R	Reportable
Postpartum Care				48.70%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Call Answer Timeliness (cat)	Y			87.75%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
1-5 Years				NA	R	Denominator fewer than 30
6-11 Years				NA	R	Denominator fewer than 30
12-17 Years				NA	R	Denominator fewer than 30
Total				NA	R	Denominator fewer than 30
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				17.53%	R	Reportable
21-40 Percent				3.90%	R	Reportable
41-60 Percent				4.55%	R	Reportable
61-80 Percent				14.29%	R	Reportable
81+ Percent				59.74%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				NA	R	Denominator fewer than 30
1 Visit				NA	R	Denominator fewer than 30
2 Visits				NA	R	Denominator fewer than 30
3 Visits				NA	R	Denominator fewer than 30
4 Visits				NA	R	Denominator fewer than 30
5 Visits				NA	R	Denominator fewer than 30
6+ Visits				NA	R	Denominator fewer than 30
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	NA	R	Denominator fewer than 30
Adolescent Well-Care Visits (awc)	Y		N	24.19%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N				NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N				NR	Measure Unselected
Ambulatory Care: Other (ambd)	N				NR	Measure Unselected

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Inpatient Utilization-- General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization-- General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Disabled (ipuc)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Other (ipud)	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N			NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N			NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N			NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected
Relative Resource Use						

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			NR	Denominator fewer than 30
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				NR	Denominator fewer than 30
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	N				NR	Measure Unselected
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N				NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N				NR	Measure Unselected
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable

Audit Review Table						
Coventry Health & Life Insurance Company dba CoventryCares of Kentucky (Org ID: 19497, SubID: 10962, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014						
The Auditor lock has been applied to this submission.						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	86.13%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				45.50%	R	Reportable
<i>Counseling for Nutrition</i>				51.34%	R	Reportable
<i>Counseling for Physical Activity</i>				40.88%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				78.83%	R	Reportable
<i>IPV</i>				89.29%	R	Reportable
<i>MMR</i>				87.83%	R	Reportable
<i>HiB</i>				87.35%	R	Reportable
<i>Hepatitis B</i>				90.27%	R	Reportable
<i>VZV</i>				89.54%	R	Reportable
<i>Pneumococcal Conjugate</i>				80.29%	R	Reportable
<i>Hepatitis A</i>				74.45%	R	Reportable
<i>Rotavirus</i>				62.53%	R	Reportable
<i>Influenza</i>				36.98%	R	Reportable
<i>Combination #2</i>				75.18%	R	Reportable
<i>Combination #3</i>				71.05%	R	Reportable
<i>Combination #4</i>				61.56%	R	Reportable
<i>Combination #5</i>				52.55%	R	Reportable
<i>Combination #6</i>				31.63%	R	Reportable
<i>Combination #7</i>				48.18%	R	Reportable
<i>Combination #8</i>				30.41%	R	Reportable
<i>Combination #9</i>				25.79%	R	Reportable
<i>Combination #10</i>				25.06%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				83.07%	R	Reportable
<i>Tdap/Td</i>				90.10%	R	Reportable
<i>Combination #1</i>				82.11%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			15.82%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Lead Screening in Children (lsc)	Y		N	60.58%	R	Reportable
Breast Cancer Screening (bcs)	Y			51.58%	R	Reportable
Cervical Cancer Screening (ccs)	Y			49.15%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			7.86%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
16-20 Years				46.04%	R	Reportable
21-24 Years				56.98%	R	Reportable
Total				50.43%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		65.23%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		61.64%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		19.38%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			23.09%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
Systemic Corticosteroid				64.20%	R	Reportable
Bronchodilator				76.11%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
5-11 Years				93.83%	R	Reportable
12-18 Years				88.96%	R	Reportable
19-50 Years				63.83%	R	Reportable
51-64 Years				53.46%	R	Reportable
Total				85.82%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				73.71%	R	Reportable
5-11 Years - Medication Compliance 75%				50.52%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
12-18 Years - Medication Compliance 50%				64.78%	R	Reportable
12-18 Years - Medication Compliance 75%				42.28%	R	Reportable
19-50 Years - Medication Compliance 50%				69.44%	R	Reportable
19-50 Years - Medication Compliance 75%				46.29%	R	Reportable
51-64 Years - Medication Compliance 50%				78.82%	R	Reportable
51-64 Years - Medication Compliance 75%				49.41%	R	Reportable
Total - Medication Compliance 50%				70.39%	R	Reportable
Total - Medication Compliance 75%				47.25%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				85.85%	R	Reportable
12-18 Years				66.94%	R	Reportable
19-50 Years				39.43%	R	Reportable
51-64 Years				38.36%	R	Reportable
Total				70.43%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			57.70%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		83.13%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
Hemoglobin A1c (HbA1c) Testing				87.04%	R	Reportable
HbA1c Poor Control (>9.0%)				39.78%	R	Reportable
HbA1c Control (<8.0%)				50.18%	R	Reportable
HbA1c Control (<7.0%)				36.08%	R	Reportable
Eye Exam (Retinal) Performed				40.51%	R	Reportable
Medical Attention for Nephropathy				80.84%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)				57.85%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		69.19%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			64.34%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				62.35%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				46.78%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				44.59%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				52.35%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				55.82%	R	Reportable
<i>7-Day Follow-Up</i>				31.98%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		79.35%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			68.89%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominat or fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		63.50%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
<i>1-5 Years</i>				NA	R	Denominat or fewer than 30
<i>6-11 Years</i>				0.39%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
12-17 Years				1.66%	R	Reportable
Total				1.13%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
1-5 Years				12.12%	R	Reportable
6-11 Years				15.72%	R	Reportable
12-17 Years				24.08%	R	Reportable
Total				20.69%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
ACE Inhibitors or ARBs				89.34%	R	Reportable
Digoxin				47.93%	R	Reportable
Diuretics				89.54%	R	Reportable
Total				89.07%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
20-44 Years				81.16%	R	Reportable
45-64 Years				87.23%	R	Reportable
65+ Years				82.47%	R	Reportable
Total				83.21%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
12-24 Months				97.20%	R	Reportable
25 Months - 6 Years				90.63%	R	Reportable
7-11 Years				96.32%	R	Reportable
12-19 Years				95.05%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
2-3 Years				37.97%	R	Reportable
4-6 Years				67.74%	R	Reportable
7-10 Years				66.48%	R	Reportable
11-14 Years				59.61%	R	Reportable
15-18 Years				51.55%	R	Reportable
19-21 Years				34.57%	R	Reportable
Total				57.34%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
<i>Initiation of AOD Treatment: 13-17 Years</i>				37.86%	R	Reportable
<i>Engagement of AOD Treatment: 13-17 Years</i>				12.69%	R	Reportable
<i>Initiation of AOD Treatment: 18+ Years</i>				32.68%	R	Reportable
<i>Engagement of AOD Treatment: 18+ Years</i>				7.09%	R	Reportable
<i>Initiation of AOD Treatment: Total</i>				32.99%	R	Reportable
<i>Engagement of AOD Treatment: Total</i>				7.43%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
<i>Timeliness of Prenatal Care</i>				84.91%	R	Reportable
<i>Postpartum Care</i>				59.12%	R	Reportable
Call Answer Timeliness (cat)	Y			78.20%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator or fewer than 30
<i>6-11 Years</i>				59.52%	R	Reportable
<i>12-17 Years</i>				59.89%	R	Reportable
<i>Total</i>				59.60%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<i><21 Percent</i>				5.84%	R	Reportable
<i>21-40 Percent</i>				2.68%	R	Reportable
<i>41-60 Percent</i>				6.57%	R	Reportable
<i>61-80 Percent</i>				12.90%	R	Reportable
<i>81+ Percent</i>				72.02%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
<i>0 Visits</i>				2.43%	R	Reportable
<i>1 Visit</i>				3.13%	R	Reportable
<i>2 Visits</i>				4.91%	R	Reportable
<i>3 Visits</i>				7.14%	R	Reportable
<i>4 Visits</i>				12.06%	R	Reportable
<i>5 Visits</i>				20.09%	R	Reportable
<i>6+ Visits</i>				50.24%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	57.73%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	43.07%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N				NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N				NR	Measure Unselected
Ambulatory Care: Other (ambd)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization-- General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Disabled (ipuc)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Other (ipud)	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N			NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N			NR	Measure Unselected

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N			NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N				NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N				NR	Measure Unselected
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable

Audit Review Table						
Humana Health Plan, Inc. (HHP) (Org ID: 22278, SubID: 11371, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014						
The Auditor lock has been applied to this submission.						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	66.91%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				56.69%	R	Reportable
<i>Counseling for Nutrition</i>				49.64%	R	Reportable
<i>Counseling for Physical Activity</i>				47.20%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				64.23%	R	Reportable
<i>IPV</i>				77.86%	R	Reportable
<i>MMR</i>				86.62%	R	Reportable
<i>HiB</i>				82.00%	R	Reportable
<i>Hepatitis B</i>				69.83%	R	Reportable
<i>VZV</i>				86.37%	R	Reportable
<i>Pneumococcal Conjugate</i>				64.48%	R	Reportable
<i>Hepatitis A</i>				73.24%	R	Reportable
<i>Rotavirus</i>				55.72%	R	Reportable
<i>Influenza</i>				35.28%	R	Reportable
<i>Combination #2</i>				54.26%	R	Reportable
<i>Combination #3</i>				51.09%	R	Reportable
<i>Combination #4</i>				44.04%	R	Reportable
<i>Combination #5</i>				37.96%	R	Reportable
<i>Combination #6</i>				23.84%	R	Reportable
<i>Combination #7</i>				33.82%	R	Reportable
<i>Combination #8</i>				21.90%	R	Reportable
<i>Combination #9</i>				19.71%	R	Reportable
<i>Combination #10</i>				18.49%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				69.83%	R	Reportable
<i>Tdap/Td</i>				71.78%	R	Reportable
<i>Combination #1</i>				67.15%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			13.25%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Lead Screening in Children (lsc)	Y		N	65.45%	R	Reportable
Breast Cancer Screening (bcs)	Y			NA	R	Denominator or fewer than 30
Cervical Cancer Screening (ccs)	Y			35.52%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			6.37%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
16-20 Years				55.93%	R	Reportable
21-24 Years				54.51%	R	Reportable
Total				55.02%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		78.39%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		80.35%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		22.49%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			NA	R	Denominator or fewer than 30
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
Systemic Corticosteroid				57.78%	R	Reportable
Bronchodilator				69.05%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
5-11 Years				92.98%	R	Reportable
12-18 Years				92.54%	R	Reportable
19-50 Years				82.35%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
51-64 Years				NA	R	Denominat or fewer than 30
Total				90.35%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				68.87%	R	Reportable
5-11 Years - Medication Compliance 75%				43.40%	R	Reportable
12-18 Years - Medication Compliance 50%				64.52%	R	Reportable
12-18 Years - Medication Compliance 75%				30.65%	R	Reportable
19-50 Years - Medication Compliance 50%				NA	R	Denominat or fewer than 30
19-50 Years - Medication Compliance 75%				NA	R	Denominat or fewer than 30
51-64 Years - Medication Compliance 50%				NA	R	Denominat or fewer than 30
51-64 Years - Medication Compliance 75%				NA	R	Denominat or fewer than 30
Total - Medication Compliance 50%				67.48%	R	Reportable
Total - Medication Compliance 75%				38.35%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				75.45%	R	Reportable
12-18 Years				56.72%	R	Reportable
19-50 Years				57.58%	R	Reportable
51-64 Years				NA	R	Denominat or fewer than 30
Total				66.37%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			50.61%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		79.73%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
Hemoglobin A1c (HbA1c) Testing				88.87%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
<i>HbA1c Poor Control (>9.0%)</i>				66.97%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				32.85%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				21.67%	R	Reportable
<i>Eye Exam (Retinal) Performed</i>				39.96%	R	Reportable
<i>Medical Attention for Nephropathy</i>				84.49%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				49.09%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		60.91%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			56.97%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				68.35%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				59.71%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				42.28%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				54.55%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				39.35%	R	Reportable
<i>7-Day Follow-Up</i>				20.99%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		80.79%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			58.70%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator or fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		45.91%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
1-5 Years				NA	R	Denominator or fewer than 30
6-11 Years				0.00%	R	Reportable
12-17 Years				0.00%	R	Reportable
Total				0.00%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
1-5 Years				NA	R	Denominator or fewer than 30
6-11 Years				40.00%	R	Reportable
12-17 Years				41.76%	R	Reportable
Total				40.27%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
ACE Inhibitors or ARBs				90.02%	R	Reportable
Digoxin				50.00%	R	Reportable
Diuretics				90.36%	R	Reportable
Total				89.93%	R	Reportable
Access/Availability of Care						

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
20-44 Years				72.68%	R	Reportable
45-64 Years				83.52%	R	Reportable
65+ Years				78.36%	R	Reportable
Total				77.16%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
12-24 Months				92.39%	R	Reportable
25 Months - 6 Years				82.52%	R	Reportable
7-11 Years				88.32%	R	Reportable
12-19 Years				85.11%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
2-3 Years				38.65%	R	Reportable
4-6 Years				59.80%	R	Reportable
7-10 Years				54.91%	R	Reportable
11-14 Years				51.39%	R	Reportable
15-18 Years				42.99%	R	Reportable
19-21 Years				24.71%	R	Reportable
Total				46.40%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				47.50%	R	Reportable
Engagement of AOD Treatment: 13-17 Years				15.00%	R	Reportable
Initiation of AOD Treatment: 18+ Years				25.59%	R	Reportable
Engagement of AOD Treatment: 18+ Years				7.15%	R	Reportable
Initiation of AOD Treatment: Total				25.91%	R	Reportable
Engagement of AOD Treatment: Total				7.27%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				69.34%	R	Reportable
Postpartum Care				51.58%	R	Reportable
Call Answer Timeliness (cat)	Y			90.82%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
1-5 Years				NA	R	Denominator or fewer than 30
6-11 Years				NA	R	Denominator or fewer than 30
12-17 Years				55.56%	R	Reportable
Total				60.71%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				13.63%	R	Reportable
21-40 Percent				8.03%	R	Reportable
41-60 Percent				9.98%	R	Reportable
61-80 Percent				20.68%	R	Reportable
81+ Percent				47.45%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				2.72%	R	Reportable
1 Visit				2.42%	R	Reportable
2 Visits				5.44%	R	Reportable
3 Visits				7.25%	R	Reportable
4 Visits				13.29%	R	Reportable
5 Visits				22.36%	R	Reportable
6+ Visits				46.53%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	62.29%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	32.60%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N				NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N				NR	Measure Unselected
Ambulatory Care: Other (ambd)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Total (ipua)	Y				R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Inpatient Utilization-- General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Disabled (ipuc)	N				NR	Measure Unselected
Inpatient Utilization-- General Hospital/Acute Care: Other (ipud)	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N			NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N			NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N			NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N				NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N				NR	Measure Unselected
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable

Audit Review Table						
University Health Care (UHC) dba Passport Health Plan (PHP) (Org ID: 1559, SubID: 4152, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014						
The Auditor lock has been applied to this submission.						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	89.35%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				86.31%	R	Reportable
<i>Counseling for Nutrition</i>				72.85%	R	Reportable
<i>Counseling for Physical Activity</i>				63.58%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				87.47%	R	Reportable
<i>IPV</i>				94.43%	R	Reportable
<i>MMR</i>				94.66%	R	Reportable
<i>HiB</i>				96.29%	R	Reportable
<i>Hepatitis B</i>				93.74%	R	Reportable
<i>VZV</i>				95.36%	R	Reportable
<i>Pneumococcal Conjugate</i>				86.77%	R	Reportable
<i>Hepatitis A</i>				84.45%	R	Reportable
<i>Rotavirus</i>				71.00%	R	Reportable
<i>Influenza</i>				56.38%	R	Reportable
<i>Combination #2</i>				83.53%	R	Reportable
<i>Combination #3</i>				80.05%	R	Reportable
<i>Combination #4</i>				71.69%	R	Reportable
<i>Combination #5</i>				63.57%	R	Reportable
<i>Combination #6</i>				50.35%	R	Reportable
<i>Combination #7</i>				58.93%	R	Reportable
<i>Combination #8</i>				47.80%	R	Reportable
<i>Combination #9</i>				43.39%	R	Reportable
<i>Combination #10</i>				41.53%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				88.89%	R	Reportable
<i>Tdap/Td</i>				93.52%	R	Reportable
<i>Combination #1</i>				88.43%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hpv)	Y			30.63%	R	Reportable
Lead Screening in Children (lsc)	Y		N	77.26%	R	Reportable
Breast Cancer Screening (bcs)	Y			56.95%	R	Reportable
Cervical Cancer Screening (ccs)	Y			55.53%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			6.00%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
16-20 Years				62.43%	R	Reportable
21-24 Years				65.16%	R	Reportable
Total				63.49%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		84.46%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		81.16%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		19.38%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			33.81%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
Systemic Corticosteroid				72.04%	R	Reportable
Bronchodilator				86.02%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
5-11 Years				94.36%	R	Reportable
12-18 Years				88.96%	R	Reportable
19-50 Years				73.11%	R	Reportable
51-64 Years				65.05%	R	Reportable
Total				88.48%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				64.47%	R	Reportable
5-11 Years - Medication Compliance 75%				38.08%	R	Reportable
12-18 Years - Medication Compliance 50%				61.13%	R	Reportable
12-18 Years - Medication Compliance 75%				32.35%	R	Reportable
19-50 Years - Medication Compliance 50%				65.29%	R	Reportable
19-50 Years - Medication Compliance 75%				39.67%	R	Reportable
51-64 Years - Medication Compliance 50%				68.66%	R	Reportable
51-64 Years - Medication Compliance 75%				52.24%	R	Reportable
Total - Medication Compliance 50%				63.51%	R	Reportable
Total - Medication Compliance 75%				36.67%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				81.19%	R	Reportable
12-18 Years				68.19%	R	Reportable
19-50 Years				54.24%	R	Reportable
51-64 Years				49.51%	R	Reportable
Total				71.77%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			51.66%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		86.00%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
Hemoglobin A1c (HbA1c) Testing				90.78%	R	Reportable
HbA1c Poor Control (>9.0%)				38.43%	R	Reportable
HbA1c Control (<8.0%)				50.61%	R	Reportable
HbA1c Control (<7.0%)				34.72%	R	Reportable
Eye Exam (Retinal) Performed				40.70%	R	Reportable
Medical Attention for Nephropathy				81.74%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)				66.43%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		61.14%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			60.20%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
Effective Acute Phase Treatment				62.67%	R	Reportable
Effective Continuation Phase Treatment				46.83%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
Initiation Phase				44.84%	R	Reportable
Continuation and Maintenance (C&M) Phase				58.26%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
30-Day Follow-Up				49.55%	R	Reportable
7-Day Follow-Up				25.00%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		89.30%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			58.33%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator or fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		56.09%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
1-5 Years				NA	R	Denominator or fewer than 30
6-11 Years				1.16%	R	Reportable
12-17 Years				4.61%	R	Reportable
Total				3.57%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
1-5 Years				21.43%	R	Reportable
6-11 Years				36.89%	R	Reportable
12-17 Years				33.66%	R	Reportable
Total				34.62%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
ACE Inhibitors or ARBs				92.00%	R	Reportable
Digoxin				61.46%	R	Reportable
Diuretics				92.68%	R	Reportable
Total				92.04%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
20-44 Years				82.58%	R	Reportable
45-64 Years				89.39%	R	Reportable
65+ Years				94.00%	R	Reportable
Total				85.17%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
12-24 Months				98.35%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
25 Months - 6 Years				90.25%	R	Reportable
7-11 Years				94.19%	R	Reportable
12-19 Years				92.92%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
2-3 Years				48.63%	R	Reportable
4-6 Years				72.94%	R	Reportable
7-10 Years				70.46%	R	Reportable
11-14 Years				66.23%	R	Reportable
15-18 Years				58.80%	R	Reportable
19-21 Years				40.66%	R	Reportable
Total				63.64%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				13.92%	R	Reportable
Engagement of AOD Treatment: 13-17 Years				2.56%	R	Reportable
Initiation of AOD Treatment: 18+ Years				25.92%	R	Reportable
Engagement of AOD Treatment: 18+ Years				2.91%	R	Reportable
Initiation of AOD Treatment: Total				25.18%	R	Reportable
Engagement of AOD Treatment: Total				2.89%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				86.89%	R	Reportable
Postpartum Care				68.67%	R	Reportable
Call Answer Timeliness (cat)	Y			77.62%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
1-5 Years				64.15%	R	Reportable
6-11 Years				74.70%	R	Reportable
12-17 Years				63.27%	R	Reportable
Total				67.86%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				5.81%	R	Reportable
21-40 Percent				2.33%	R	Reportable
41-60 Percent				4.65%	R	Reportable
61-80 Percent				12.09%	R	Reportable
81+ Percent				75.12%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				0.76%	R	Reportable
1 Visit				1.27%	R	Reportable
2 Visits				1.69%	R	Reportable
3 Visits				4.13%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
4 Visits				8.30%	R	Reportable
5 Visits				17.62%	R	Reportable
6+ Visits				66.24%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	74.77%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	51.37%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	Y				R	Reportable
Ambulatory Care: Disabled (ambc)	Y				R	Reportable
Ambulatory Care: Other (ambd)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	Y				R	Reportable
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Other (iadd)	Y	Y			R	Reportable
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y	Y			R	Reportable
Mental Health Utilization: Disabled (mptc)	Y	Y			R	Reportable
Mental Health Utilization: Other (mptd)	Y	Y			R	Reportable
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y	Y			R	Reportable
Antibiotic Utilization: Disabled (abxc)	Y	Y			R	Reportable
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				NR	Plan chose not to report
Enrollment by Product Line: Dual Eligibles (enpb)	Y				NR	Plan chose not to report
Enrollment by Product Line: Disabled (enpc)	Y				NR	Plan chose not to report
Enrollment by Product Line: Other (enpd)	Y				NR	Plan chose not to report
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable

Audit Review Table						
WellCare Health Insurance of Illinois, Inc. dba WellCare of Kentucky, Inc. (Org ID: 8732, SubID: 11095, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014						
The Auditor lock has been applied to this submission.						
Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	91.32%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				43.80%	R	Reportable
<i>Counseling for Nutrition</i>				41.36%	R	Reportable
<i>Counseling for Physical Activity</i>				40.39%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				72.99%	R	Reportable
<i>IPV</i>				86.86%	R	Reportable
<i>MMR</i>				87.35%	R	Reportable
<i>HiB</i>				85.89%	R	Reportable
<i>Hepatitis B</i>				79.32%	R	Reportable
<i>VZV</i>				90.02%	R	Reportable
<i>Pneumococcal Conjugate</i>				75.67%	R	Reportable
<i>Hepatitis A</i>				68.13%	R	Reportable
<i>Rotavirus</i>				54.26%	R	Reportable
<i>Influenza</i>				29.93%	R	Reportable
<i>Combination #2</i>				64.96%	R	Reportable
<i>Combination #3</i>				62.04%	R	Reportable
<i>Combination #4</i>				49.64%	R	Reportable
<i>Combination #5</i>				41.61%	R	Reportable
<i>Combination #6</i>				25.06%	R	Reportable
<i>Combination #7</i>				36.01%	R	Reportable
<i>Combination #8</i>				21.90%	R	Reportable
<i>Combination #9</i>				18.98%	R	Reportable
<i>Combination #10</i>				17.52%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				80.77%	R	Reportable
<i>Tdap/Td</i>				88.08%	R	Reportable
<i>Combination #1</i>				79.23%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			20.44%	R	Reportable
Lead Screening in Children (lsc)	Y		N	61.11%	R	Reportable
Breast Cancer Screening (bcs)	Y			51.47%	R	Reportable
Cervical Cancer Screening (ccs)	Y			48.18%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			7.57%	R	Reportable
Chlamydia Screening in Women (chl)	Y					

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
16-20 Years				44.49%	R	Reportable
21-24 Years				54.68%	R	Reportable
Total				48.69%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		67.27%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		60.24%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		17.59%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			23.27%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				65.07%	R	Reportable
<i>Bronchodilator</i>				79.61%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
5-11 Years				95.12%	R	Reportable
12-18 Years				89.60%	R	Reportable
19-50 Years				66.88%	R	Reportable
51-64 Years				59.71%	R	Reportable
Total				85.67%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
5-11 Years - Medication Compliance 50%				61.92%	R	Reportable
5-11 Years - Medication Compliance 75%				34.16%	R	Reportable
12-18 Years - Medication Compliance 50%				56.72%	R	Reportable
12-18 Years - Medication Compliance 75%				29.35%	R	Reportable
19-50 Years - Medication Compliance 50%				67.12%	R	Reportable
19-50 Years - Medication Compliance 75%				43.13%	R	Reportable
51-64 Years - Medication Compliance 50%				77.71%	R	Reportable
51-64 Years - Medication Compliance 75%				59.64%	R	Reportable
Total - Medication Compliance 50%				61.65%	R	Reportable
Total - Medication Compliance 75%				35.03%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
5-11 Years				85.26%	R	Reportable
12-18 Years				72.87%	R	Reportable
19-50 Years				48.12%	R	Reportable
51-64 Years				45.68%	R	Reportable
Total				71.61%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			55.99%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		82.95%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				88.78%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>				40.61%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				50.49%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				39.47%	R	Reportable
<i>Eye Exam (Retinal) Performed</i>				43.66%	R	Reportable
<i>Medical Attention for Nephropathy</i>				82.68%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				60.00%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						
Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		61.25%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			61.48%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				52.29%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				37.61%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				61.49%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				69.62%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				57.18%	R	Reportable
<i>7-Day Follow-Up</i>				33.82%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		82.24%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			70.08%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			82.14%	R	Reportable
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		66.58%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
1-5 Years				NA	R	Denominator or fewer than 30
6-11 Years				0.81%	R	Reportable
12-17 Years				1.56%	R	Reportable
Total				1.31%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
1-5 Years				19.51%	R	Reportable
6-11 Years				22.24%	R	Reportable
12-17 Years				26.66%	R	Reportable
Total				25.00%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
ACE Inhibitors or ARBs				91.21%	R	Reportable
Digoxin				53.66%	R	Reportable
Diuretics				92.09%	R	Reportable
Total				91.24%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
20-44 Years				84.36%	R	Reportable
45-64 Years				91.05%	R	Reportable
65+ Years				88.94%	R	Reportable
Total				86.91%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
12-24 Months				97.49%	R	Reportable
25 Months - 6 Years				92.02%	R	Reportable
7-11 Years				96.30%	R	Reportable
12-19 Years				95.22%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
2-3 Years				42.32%	R	Reportable
4-6 Years				69.99%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
7-10 Years				69.13%	R	Reportable
11-14 Years				63.74%	R	Reportable
15-18 Years				55.38%	R	Reportable
19-21 Years				38.20%	R	Reportable
Total				60.36%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				41.26%	R	Reportable
Engagement of AOD Treatment: 13-17 Years				16.76%	R	Reportable
Initiation of AOD Treatment: 18+ Years				30.36%	R	Reportable
Engagement of AOD Treatment: 18+ Years				5.73%	R	Reportable
Initiation of AOD Treatment: Total				30.79%	R	Reportable
Engagement of AOD Treatment: Total				6.16%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				87.29%	R	Reportable
Postpartum Care				51.41%	R	Reportable
Call Answer Timeliness (cat)	Y			80.43%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
1-5 Years				NA	R	Denominator or fewer than 30
6-11 Years				62.65%	R	Reportable
12-17 Years				66.29%	R	Reportable
Total				65.33%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				4.52%	R	Reportable
21-40 Percent				1.98%	R	Reportable
41-60 Percent				5.93%	R	Reportable
61-80 Percent				15.25%	R	Reportable
81+ Percent				72.32%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				3.32%	R	Reportable
1 Visit				5.61%	R	Reportable
2 Visits				5.36%	R	Reportable
3 Visits				6.89%	R	Reportable
4 Visits				8.67%	R	Reportable
5 Visits				22.96%	R	Reportable
6+ Visits				47.19%	R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	59.75%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	41.85%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N				NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N				NR	Measure Unselected
Ambulatory Care: Other (ambd)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N			NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N			NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N			NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected
Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	Y				R	Reportable
Total Membership (t1m)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N				NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N				NR	Measure Unselected
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable